Evaluating risk factors for Trastuzumab-Deruxtecan Pneumonitis in patients with metastatic breast cancer
In this cohort, prior treatment with abemaciclib may be a risk factor for T-DXd pneumonitis. Conversely, pre-treatment chest imaging abnormalities, prior immune checkpoint inhibitor treatment, and prior chest or breast radiation did not increase the risk of T-DXd pneumonitis. Larger studies are warranted to validate these findings toward an improved understanding of risk factors for pneumonitis after T-DXd exposure.
Authors
- Jonathan E. Schoenhals (ORCID: https://orcid.org/0000-0002-8760-1620)
- Ian Bentley (ORCID: https://orcid.org/0000-0002-4442-2761)
- Margaret E. Gatti‐Mays (ORCID: https://orcid.org/0000-0001-8914-2897)
- Sachin R. Jhawar (ORCID: https://orcid.org/0000-0001-8604-4757)
- Vincent Esguerra
- Daniel G. Stover (ORCID: https://orcid.org/0000-0001-9003-8165)
- Jianing Ma (ORCID: https://orcid.org/0009-0001-3621-8744)
- R Wilson (ORCID: https://orcid.org/0000-0002-2336-8946)
- Jonathan Henricks
- Tyler Haddad (ORCID: https://orcid.org/0000-0002-2583-2394)
- M.J. Wert
- Jing Gennie Wang (ORCID: https://orcid.org/0000-0001-5705-9917)
- Omair Ahmed
- Pavnesh Kumar
- Kevin Ho (ORCID: https://orcid.org/0000-0002-9803-4465)
- Kai Johnson
Institutions
- The Ohio State University Wexner Medical Center (US)
- The Ohio State University (US)
Publication Details
- Journal
- Breast Cancer Research
- Published
- 2025-02-03
- DOI
- https://doi.org/10.1186/s13058-025-01967-1
- Citations
- 1
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 1.52